ReviewCurrent osteoporosis reports2023
Advances in Osteosarcoma.
Review in Current osteoporosis reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 3 syntheses or guidelines pooled it, 105 citations in OpenAlex.
- Prognostic value of the immune-inflammatory indices in osteosarcoma: a systematic review and meta-analysis.World journal of surgical oncology · 2026Pooled it
- In vivo Testing of Nanotherapeutics for Osteosarcoma Treatment: Translational Challenges and Solutions.International journal of nanomedicine · 2025Pooled it
- Bibliometric analysis of targeted immunotherapy for osteosarcoma-current knowledge, hotspots and future perspectives.Frontiers in immunology · 2024Pooled it
- The Osteosarcoma Tumor Microenvironment: From Cellular Interactions to Advanced Preclinical Models.Cancers · 2026Review
- Preliminary analysis of chromatin accessibility in osteosarcoma tissues.Clinics (Sao Paulo, Brazil) · 2026Article
- Single-cell transcriptomics reveals glycolytic heterogeneity and identifies STC2 as a key regulator of metabolic reprogramming in osteosarcoma.Molecular and cellular biochemistry · 2026Article
- Survival improvement and widening social disadvantage-related disparities in osteosarcoma: a Surveillance, Epidemiology, and End Results-based retrospective cohort study.Translational cancer research · 2026Article
- Synthesis of Gd-DOTA-BMTP and its application in gadolinium neutron capture therapy for osteosarcoma.Journal of cancer research and clinical oncology · 2026Article
- From Smart Hydrogel Design to 4D-Printed Scaffolds: Emerging Paradigms in Precision Drug Delivery and Regenerative Wound Therapy.Gels (Basel, Switzerland) · 2026Review
- Omacetaxine reduces c-Myc expression and demonstrates antitumor effects in osteosarcoma.Scientific reports · 2026Article
- Does mifamurtide affect the elimination of high-dose methotrexate in children with osteosarcoma?Cancer chemotherapy and pharmacology · 2026Article
- FOXA2 promotes the occurrence and development of osteosarcoma cells by regulating ferroptosis through the Rheb/mTOR axis.World journal of surgical oncology · 2026Article
- Article
- The MDM2-p53 Axis in Osteosarcoma: Current Understanding of Regulatory Mechanisms and Targeted Therapeutic Strategies.Pharmaceuticals (Basel, Switzerland) · 2026Review
- S100A13 transcriptionally activated by SP1 facilitates osteosarcoma metastasis.Discover oncology · 2026Article
- Harnessing natural compounds and nanotechnology for miRNA-based osteosarcoma therapy.RSC advances · 2026Review
- Emerging research themes in drug resistance in osteosarcoma: a 25-year bibliometric and visualized analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- HDACi induces apoptosis of osteosarcoma cells by inhibiting the MAPK pathway.Scientific reports · 2026Article
- The Multitalented Marvels: Exploring the Versatile Potential of Natural Products in Osteosarcoma Treatment.Cancer informatics · 2026Review
- Lenvatinib induces ferroptosis-related changes in osteosarcoma cells involving the p-STAT3/p53/xCT axis.Frontiers in oncology · 2026Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis article gives a brief overview of the most recent developments in osteosarcoma treatment, including targeting of signaling pathways, immune checkpoint inhibitors, drug delivery strategies as single or combined approaches, and the identification of new therapeutic targets to face this highly heterogeneous disease. RECENT
findingsOsteosarcoma is one of the most common primary malignant bone tumors in children and young adults, with a high risk of bone and lung metastases and a 5-year survival rate around 70% in the absence of metastases and 30% if metastases are detected at the time of diagnosis. Despite the novel advances in neoadjuvant chemotherapy, the effective treatment for osteosarcoma has not improved in the last 4 decades. The emergence of immunotherapy has transformed the paradigm of treatment, focusing therapeutic strategies on the potential of immune checkpoint inhibitors. However, the most recent clinical trials show a slight improvement over the conventional polychemotherapy scheme. The tumor microenvironment plays a crucial role in the pathogenesis of osteosarcoma by controlling the tumor growth, the metastatic process and the drug resistance and paved the way of new therapeutic options that must be validated by accurate pre-clinical studies and clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.